E-pitching event | Best EU-backed Biotech innovators  


For the second time, we will introduce you to six of Europe’s most disruptive Biotech innovators with groundbreaking proposals and a promising market in the fields of Biomedical Engineering, Biomedicine, Pharma, Healthtech and Neuroscience. 

Together with the European Commission, Dealflow.eu is thrilled to welcome this e-pitching event organised together with EurA AG, on 01 March 2023, from 10:30 AM to 12:00 PM (CET), to find the most encouraging Biotech innovators. 

Sign Up to explore your next investment opportunity!


Following the 2020’s record of $29 billion in capital through IPOs for biotech companies, 2021 and 2022 saw a pullback in many investment verticals. While 2022 was not a great year for European startups in general due to the war in Ukraine and consequent inflation, biotechnological firms managed to hold venture capital funding and the sector continues relatively stable.  

The scientific ecosystem in Europe is thriving, in 2021 European scholars produced almost twice as many scientific publications as the United States. This translates into a consistent growth in drug development and in approvals from the European Medicines Agency (EMA). 

One of the biggest challenges for European biotech is the talent gap which is now considered to be slowly closing. While there is still higher demand than supply, STEM talent is growing, and serial entrepreneurs are emerging in Europe and relocating from the US. 


During the e-pitching event, the following six startups and innovators will introduce their innovative business cases.  


Most Groundbreaking Biotech Innovators: 

Bioemtech – Biomedical Engineering   

PediDose: decision support tool for all Nuclear Medicine doctors to predict internal dosimetry in pediatric cancer patients. An intelligent approach for personalised absorbed dose assessment, before the nuclear examination. Precise AI medicine, fast solution, cost-effective, license-based. 

0,9M€ SW research projects. PediDose an FF4EuroHPC success story, pilot cases (Competitors: MIRDsoft, OLINDA) 

€0,4M sought – Greece.  



Cherry Biotech – Biotech/Pharma 

Alternative to animal experiments, Cherry Biotech develops an Organ-On-Chips patented platform to better predict drug effects on the human body based on their 3D vascularised immuno-competent organoids technology. With their CubiX Platform and proprietary biological models, they help pharma/biotechs in their early drug development phases and Hospitals to perform a therapeutic evaluation before administration to patients. 

Winner of the EIC Transition award. Partnered with key pharma companies and academic centres like Novo Nordisk, Sanofi and Gustave Roussy. 

€5M sought – France.  


Nadir Plasma & Polymers – Biomedicine 

Cold plasma devices and advanced polymer composites for biomedical applications. Recognised as a key innovator by the EC Innovation Radar initiative for plasma surface functionalisation of scaffolds and devices, and active polymer masterbatches for scaffolds and medical devices. 

Innovative SME in Italy, which is patent-granted in the main countries of the world and is already on the R&D market.  

€2M– Italy.  


Radiomics – HealthTech 

Radiomics is an AI-powered research organisation providing image-based insights to support clinical trials and research design making. Radiomics optimises pharmaceutical clinical trials and drug development trajectories through advanced image analysis technology and by providing decision support tools to clinicians to ensure that patients can benefit from a personalised medicine approach that enables them to receive the best possible treatment.  

Partner with 5 of the top 20 Pharma companies, nominated for HTID & ZELSIF awards.  

€10M sought – Belgium. 


Starlab – Neuroscience 

Central Nervous System (CNS) diseases affect approximately 20% of the world’s population. At the same   time, CNS treatment development is the riskiest business of all pharmaceutical domains. Starlab provides the combination of Electroencephalography (EEG), one of the most cost-effective and easy-to-use neuroimaging technologies, with modern AI approaches to offer a solution for efficient CNS treatment development. NeurodegenerationAI is an EEG-based brain test that provides an objective score for the detection of cognitive impairment that can be used for informed recruitment in clinical trials to select those patients at the disease’s earliest stage and therefore with the largest probability of treatment efficacy. 

€0,5M sought – Spain. 


TIRmed – Pharma 

TIRmed Pharma is developing next-generation proprietary topical medication against skin diseases, at the forefront of oligonucleotide treatments of Atopic Dermatitis (AD). The company highlights are: strong efficacy data in the study with dogs suffering from AD; one of the first companies with proof of ability to deliver an oligonucleotide topically; established bioanalytical analyses; supply chain, with GMP capabilities, set up. 

€1,8M sought – Sweden. 


More about the Innovation Radar 

The Innovation Radar is a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation projects. Its goal is to allow every citizen, public official, professional and businessperson to discover the outputs of EU innovation funding and give them a chance to seek out innovators who could follow in the footsteps of companies such as Skype, TomTom, ARM Holdings, all of whom received EU funding in their early days.

To learn more about the Innovation Radar,  visit https://www.innoradar.eu/


More about Dealflow.eu

Supported by the European Commission, Dealflow.eu discovers and supports the most promising EU-funded startups and connects them with relevant investors and corporates. The initiative was launched to help groundbreaking innovations secure the funding needed for their future commercialisation by offering them tailored support and matchmaking services.

To learn more about Dealflow.eu, visit https://dealflow.eu/